Latigo Reports Q2 Loss of $25.8M, NEJM Publication, and Cash Runway into 2029
LTGO sits 31% above its 52-week low of $17.22.
Summary
Latigo Biotherapeutics reported Q2 2026 results with a $25.8 million net loss, highlighted NEJM publication of positive onzotrigine data, and confirmed cash runway into 2029 following its upsized IPO.
Key Events · Earnings and Guidance · LTGO
-
NEJM Publishes Positive Onzotrigine Data
The New England Journal of Medicine published positive Phase 2 abdominoplasty results for onzotrigine, meeting the primary endpoint with high statistical significance and demonstrating opioid-sparing potential.
-
Q2 Net Loss of $25.8M
Net loss was $25.8 million for Q2 2026, with R&D expenses of $21.2 million and G&A of $4.6 million. Cash and equivalents stood at $55.0 million as of June 30, 2026.
-
Cash Runway into 2029
Including net proceeds from the $397.4 million upsized IPO completed in August 2026, current cash is projected to fund operations into 2029.
-
Phase 3 Program Initiation Planned H2 2026
Latigo plans to initiate a Phase 3 bunionectomy trial and an open-label safety trial for onzotrigine in H2 2026, with topline results expected in H2 2027.
Analysis · LTGO · Life Sciences
Latigo's first quarterly report as a public company delivers several material updates beyond the headline loss. The NEJM publication of positive onzotrigine Phase 2 abdominoplasty data is a significant validation for a clinical-stage biotech — only the second original research publication for a novel acute pain drug in NEJM in 15 years. The company also confirmed cash of $55 million as of June 30, 2026, with projected runway into 2029 including the $397.4 million IPO proceeds, removing near-term financing risk. The appointment of a former FDA deputy director as SVP of regulatory affairs strengthens the team ahead of the planned Phase 3 program initiation in H2 2026.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LTGO was trading at $22.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $17.22 to $25.93. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.